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Abstract
Objective
Gestational Diabetes Mellitus (GDM) increases the risk of type 2 diabetes. A register can
be used to follow-up high risk women for early intervention to prevent progression to type 2
diabetes. We evaluate the performance of the world’s first national gestational diabetes
register.
Research design and methods
Observational study that used data linkage to merge: (1) pathology data from the Australian
states of Victoria (VIC) and South Australia (SA); (2) birth records from the Consultative
Council on Obstetric and Paediatric Mortality and Morbidity (CCOPMM, VIC) and the South
Australian Perinatal Statistics Collection (SAPSC, SA); (3) GDM and type 2 diabetes regis-
ter data from the National Gestational Diabetes Register (NGDR). All pregnancies regis-
tered on CCOPMM and SAPSC for 2012 and 2013 were included–other data back to 2008
were used to support the analyses. Rates of screening for GDM, rates of registration on
the NGDR, and rates of follow-up laboratory screening for type 2 diabetes are reported.
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Results
Estimated GDM screening rates were 86% in SA and 97% in VIC. Rates of registration on
the NGDR ranged from 73% in SA (2013) to 91% in VIC (2013). During the study period
rates of screening at six weeks postpartum ranged from 43% in SA (2012) to 58% in VIC
(2013). There was little evidence of recall letters resulting in screening 12 months follow-up.
Conclusions
GDM Screening and NGDR registration was effective in Australia. Recall by mail-out to
young mothers and their GP’s for type 2 diabetes follow-up testing proved ineffective.
Introduction
Women with previous GDM have a sevenfold higher risk of developing type 2 diabetes mellitus
than women who have not had GDM [1]. Recall registers have a well-recognised role for manag-
ing populations at high risk. Australia has had two registries for gestational diabetes mellitus
(GDM) that have been created to support the follow-up of mothers who have had GDM to help
prevent progression to type 2 diabetes or identify it at an early stage. There was a previous state-
based South Australia Gestational Diabetes Recall Register (2002-June 2011) and a current
National Gestational Diabetes Register (NGDR, from July 2011). The NGDR is managed by the
National Diabetes Support Scheme (NDSS) under the auspices of Diabetes Australia. Women
meeting the criteria for GDM are registered with NGDR by diabetes educators. These registers
support follow-up of women for regular diabetes screening and lifestyle modification to reduce
their risk of developing type 2 diabetes through periodic letters to both the patient and the GP.
Registration on the GDM registers is not mandated. In addition to the GDM registers, each state
maintains a Birth Register with mandated reporting of all births and includes recording GDM.
Lifestyle modification can reduce type 2 diabetes risk by 58% [2,3]. The NGDR provides
information and regular screening reminder. It is administered by Diabetes Australia, an
NGO, on behalf of the Australian Government. Women are registered with NGDR following
diagnosis of GDM at the 26–28 week Oral Glucose Tolerance Test (OGTT) which entitles
them to subsidised medication and equipment for managing diabetes during their pregnancy.
Our study sought to evaluate for the first time the extent to which a National Gestational
Diabetes Register contributes to prevention of subsequent diabetes among women diagnosed
with GDM. Specifically this study used data linkage to evaluate:
1. The completeness of state-based GDM screening during pregnancy
2. The completeness of registration of mothers with GDM on the NGDR
3. The impact of register letters on mothers and GPs to influence mothers to have follow-up
blood tests for diabetes risk as indicated through pathology test results.
The study linked information from the NGDR, perinatal data collections from two states,
and blood test results from pathology laboratories in both states.
Materials and methods
This study was part of a larger project, Mothers after Gestational Diabetes in Australia
(MAGDA), which took a system approach to prevention of progression to type 2 diabetes
among women previously diagnosed with GDM [4]. The study was approved by the relevant
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ethics committees; SA Health Human Research Ethics Committee HREC/14/SAH/93 and
Department of Health, Victoria HREC 14/12. All data including NGDR, State perinatal, and
pathology laboratory data was fully anonymised at-source with researchers having access to fully
anonymised data only. Given the anonymous nature of the data, all ethics committees waived
any requirement for patient informed consent. The study design is described below (Fig 1).
Data sources and availability
Laboratory data came from the Australian states of Victoria (population 5,574,500) and South
Australia [5] (population 1,645,000), which combined make up approximately 32% of the Aus-
tralian population (2011 census data, Australian Bureau of Statistics, 2012). Data were supplied
by four providers (SA Pathology, Healthscope, Melbourne Pathology, and Dorevitch Pathol-
ogy). One provider (SA Pathology) processes samples from public hospitals and community
samples; the other three primarily process private hospitals and community samples. These
laboratories are the predominant pathology providers in the two states studied and for our
study population (see results later). Diabetes-related test results from these laboratories during
the pre and post-natal time period were found for 69% of our Victorian cohort and 82% of our
South Australian cohort.
Birth records came from the Consultative Council on Obstetric and Paediatric Mortality
and Morbidity (CCOPMM) in Victoria and South Australian Perinatal Statistics Collection
(SAPSC). Reporting by hospitals is mandatory. Data were available in South Australia from
2008 to 2013 and in Victoria from 2009 to 2013. We accounted for birth plurality to ensure the
total number of pregnancies were being considered rather than births.
Fig 1. Study design (data acquisition, linkage and analysis). Note: ‘HASHES for record linkage’ refer to strings of letters and
numbers generated by a one-way mathematical algorithm—that is, a function which it is infeasible to reverse or invert. Such
algorithms are known as cryptographic ‘hash’ functions. Such hashes are generated whilst the data is still held by the original
custodian of the data. When data is exported, person identifiers are left behind leaving only the non-reversible ‘hashes’. These are
subsequently used to undertake privacy-preserving record linkage.
https://doi.org/10.1371/journal.pone.0200832.g001
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GDM and type 2 diabetes register data were from the NDSS database, which has operated
NGDR as a subset since July 2011. GDM and type 2 diabetes diagnostic information was avail-
able from 2008 to December 2015.
Data acquisition and linkage
Legislation specifically prohibits release of person identifiers from CCOPMM and SAPSC. Pri-
vacy considerations for pathology laboratories were also a barrier to extracting person-identifi-
able data. To overcome this, we utilised a privacy-protecting data acquisition and linkage
system (GRHANITE) [6]. GRHANITE creates probabilistic, hashed data linkage key signa-
tures whilst data are still held within the bounds of the data custodian’s organisation. These
signatures are based on surname, forename, date of birth, postcode, and 5 digits of the medi-
care ID when available. To comply with legislation the full medicare ID is never used. The
algorithm for GRHANITE’s key generator was designed and tested alongside traditional per-
son-identifiable data linkage mechanisms to validate that similar sensitivity and specificity
data linkage profiles were achieved [7]. GRHANITE hashed signatures cannot be reversed,
guaranteeing anonymity when extracted. The GRHANITE automated periodic data extraction
and secure, encrypted data transmission from each data custodian organisation to the
MAGDA Study GRHANITE databank were curated by The University of Melbourne.
The record linkage system gives no mechanism to manually validate linkage sensitivity and
specificity because of its privacy-protecting nature, although these can be estimated. All moth-
ers who are registered on NGDR should have a corresponding perinatal birth record with a
GDM diagnosis. The days between NGDR registration and birth in the linked records were
examined with an alignment between NGDR registration and birth expected. This relationship
was examined for all registrations in Victoria and South Australia for 2012 and 2013.
Study population
The overarching study population and record linkage included all records from the state birth
records (CCOPMM and SAPSC), the NGDR and pathology laboratory data between 2008 and
2013 inclusive. Sub-populations were utilised with different start and stop dates for different
parts of the analysis–for example data was analysed before and after the introduction of the
NGDR to assess differences in laboratory testing after birth, and the core sub-population ana-
lysed activity from six months after the establishment of the NGDR until 2013. In some analy-
ses, the use of first pregnancy only was applied to ensure mothers could not have had a
previous GDM diagnosis and could not have participated in any NDSS datasets. These linked
data contained data linkage keys, information on number of previous pregnancies, baby date
of birth, maternal age at birth, GDM diagnosis (if present), pregnancy plurality, ethnicity, and
geographical location (Local Government Area). The NGDR provided data on date of registra-
tion from register inception on 1 July 2011 until 31 December 2014. The NGDR has fixed
dates after registration when bulk mail-outs occur so the study dataset itself did not contain
actual dates of mail-out but the times when mail-outs to mothers and GP’s were undertaken
for each mother was known. Data prior to commencement of the NGDR was available from
2008, although a GDM diagnosis was overwritten if a mother converted to type 2 diabetes
before NGDR inception in July 2011. The NGDR data also included data linkage keys,
expected baby date of birth, ethnicity, geographical location (Statistical Areas Level 2), moth-
er’s age at registration, and socio-economic status (Index of Relative Socio-Economic Advan-
tage and Disadvantage, 2011 Australian Census) [8]. Pathology data aimed to capture the
majority of diabetes-related testing in the female population in Victoria and South Australia
but logistical constraints meant it was not possible to collect data from all pathology providers.
Impact of a national gestational diabetes register
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All blood glucose (BGLU), glycated haemoglobin (HbA1c), oral glucose tolerance test
(OGTT), and glucose challenge test (GCT) data for women from 2008–2014 were extracted
from participating providers. We collected data linkage keys, date of test (collection), type of
test, test result, age at test, and geographical location (Local Government Area). For the main
study analysis examining NGDR recall performance metrics, we concentrated on birth records
from 2012 to 2013 and their corresponding registrations. This approach provided two years of
registration data with a minimum of one year of follow-up laboratory testing data. We also
examined rates of GDM screening and registration likely to have been triggered by NGDR.
Defining screening, registration and recall
Pathology data (BGLU, HbA1c, OGTT, and GCT) were linked to the CCOPMM and SAPSC
databases to estimate screening rates. GDM screening was recorded for a woman if a blood test
result during the normal gestation period for a baby delivered in 2012 or 2013 was linked to a
birth record, with the limitation that any blood test for glycaemia during pregnancy was treated
as a possible GDM screen. The same linkage was used to estimate pathology coverage rates with
the limitation that women who changed pathology provider to one not supplying us with data
would not be accounted for. Because missing data affects those who have GDM and those with-
out, mothers who use alternate laboratories do not affect the accuracy for assessment of GDM
incidence. This assumes missing data was missing at random and we do not believe there is a
specific reason that women would actively choose alternative laboratories–most will attend the
laboratory specified by their clinician.The GDM screening variable was cross-tabulated with the
CCOPMM and SAPSC database variable defining a pregnancy as GDM-affected. The rationale
for this was based upon the assumption that all women should be screened. There should be no
difference in the proportion of women screened, whether GDM was diagnosed or not.
The GDM register did not record the date of delivery–only the date of registration of GDM.
The pattern of GDM register registration relative to the date of delivery was determined after
record linkage and revealed a peak in registration at 68 days (9.7 weeks) prior to birth, aligned
to 1–2 weeks after the near universal, but voluntary, GDM screening test carried out at 26–28
weeks. To ensure the temporal shift between registration and delivery was accounted for in
comparative statistics, we included GDM registrations from the last 68 days of the 2011 calen-
dar year in the numerator. Specifically, the 68 day temporal adjustment allowed a population
comparison between the GDM register records and dates of delivery as recorded on the
CCOPMM and SAPSC databases during 2012 and 2013. Because 68 days represents the peak
alignment between the GDM register registrations and dates of delivery there will be some
births missed in the population comparison due the vagaries of early births. The alignment is
the closest that can be done to effect a comparison across the whole GDM register population
and the whole population perinatal birth records.
Estimating the effectiveness of the recall was done by firstly defining the recall population.
Only women with GDM are registered with NGDR. The woman’s date of registration was used in
this analysis and we allowed up to 42 weeks gestation. NGDR recall was defined as a woman who
should have received a reminder letter from the NGDR and then had a blood test at a time consis-
tent with mail-out (i.e. women tested before mail-out were not classified as recalled by the NGDR
(Fig 2)). Operational timelines for mail-outs were sourced directly from the NGDR. NGDR
reminder letters are mailed out 8–16 weeks after registration (Fig 2). An analysis of follow-up dia-
betes screening was done by comparing the pattern of diabetes screening occurring prior to the
NGDR’s establishment to further elucidate impact of the mail-out. We also examined patterns of
diabetes screening during the first 12 months postpartum to capture any activity consistent with
the NGDR annual diabetes screening reminder mail-out ten months after registration.
Impact of a national gestational diabetes register
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Data management, analyses, and visualisation were done in Microsoft SQL Server, Micro-
soft Excel 2013, and Stata 14 [9,10,11].
Results
Record linkage
A total of 12,235,355 data records and 6,714,844 data linkage keys contributed to the 2012 to
2013 analysis. Victoria had higher record numbers than South Australia, broadly reflecting the
difference in each State’s population. Table 1 illustrates the raw record numbers prior to clean-
ing and data linkage with the OGTT, GCT, HBA1c, and BGLU columns being the total num-
ber of tests available from each laboratory. Of 13,316 records found on the NGDR for 2012–
2013 (SA and Vic combined), after cleaning and record linkage12,214 mothers were recorded
Fig 2. Timeline of GDM test and type 2 diabetes follow-up in relation to the NGDR NGDR—national gestational
diabetes register.
https://doi.org/10.1371/journal.pone.0200832.g002
Table 1. Raw data availability in Victoria and South Australia (2012 and 2013). (Includes pathology data prior and subsequent to birth. HbA1c almost all used at one
year follow-up).
Victoria
Laboratory OGTT GCT HBA1c BGLU NDSS GDM Register South Australia Birth Register (SAPSC) Victoria Birth Register (CCOPMM)
Laboratory A 35,284 10,262 150,483 594,620
Laboratory B 27,817 11,538 144,564 590,330
Laboratory C 51 146 905 10,131
Laboratory D 52,319 15,626 80,442 484,385
Total 115,471 37,572 376,394 1,679,466 10,819 332 150,031
South Australia
Laboratory OGTT GCT HBA1c BGLU NDSS GDM SAPSC CCOPMM
Laboratory A 9,177 5,055 49,394 95,649
Laboratory B 5 4 0 120
Laboratory C 19,333 30,942 104,966 1,312,377
Total 28,515 36,001 154,360 1,408,146 2,497 40,599 5,973
https://doi.org/10.1371/journal.pone.0200832.t001
Impact of a national gestational diabetes register
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with GDM on the NGDR. Of these, 10,599 had corresponding birth records on state perinatal
birth record systems (indicative linkage sensitivity 86.7%).
Fig 3. NGDR registration in days prior to and after baby birth for 2012 and 2013 NGDR—national gestational diabetes register.
https://doi.org/10.1371/journal.pone.0200832.g003
Table 2. GDM screening and follow-up rates.
Victoria (Mothers with GDM diagnosis)
Year Women Screen available % 6 week follow-up test %
2010 3864 1434 37.1 710 49.5
2011 4212 1549 36.8 872 56.3
2012 5413 2672 49.4 1560 58.4
2013 6045 3330 55.1 1892 56.8
South Australia (Mothers with GDM diagnosis)
Year Women Screen available % 6 week follow-up test %
2010 1091 832 76.3 358 43.0
2011 1393 1112 79.8 470 42.3
2012 1468 1205 82.1 525 43.6
2013 1636 1355 82.8 599 44.2
 population where a prenatal GDM screening record (OGTT / GCT) was available
 population of those with an initial GDM diagnostic record where a further GDM screening record was available at the time of a 6-week postnatal checkup
https://doi.org/10.1371/journal.pone.0200832.t002
Impact of a national gestational diabetes register
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NGDR registration peaked 68 days before the baby birth date (Fig 3) and inspection of the
distribution revealed examples of linkages associated with pregnancies outside the study
period of 2012–2013 (i.e. registrations related to prior or subsequent pregnancies).
GDM screening
OGTT and GCT laboratory test data from 2009–2014 was linked to the state perinatal data col-
lections for mothers who had a GDM diagnosis in the years 2010–2013. Table 2 details the
number of women diagnosed with GDM 2010–2013 and gives the number of these women
that we had prenatal GDM diagnostic laboratory tests available for. The table also illustrates
the number of women who have a GDM screening test record available aligned to a routinely
planned postnatal checkup at six weeks. Using this data, we aimed to estimate the percentage
of mothers missing GDM screening in 2013:
Victoria:
• For mothers with no GDM diagnosis, screening data was available for 50.0%
• For mothers with a GDM diagnosis, screening data was available for 55.1%
South Australia:
• For mothers with no GDM diagnosis, screening data was available for 68.6%
• For mothers with a GDM diagnosis, screening data was available for 82.8%
In both South Australia and Victoria we observed that those with a positive diagnosis had a
higher proportion of mothers tested for GDM than those without (55.1%–50.0% = 5.1% VIC,
82.8%–68.7% = 14.2% SA). Given that all mothers with a GDM diagnosis must have been
screened, the lower rate of GDM in those without available test data may be explained by a
population of mothers who were not screened.
From the above, in Victoria, 5.1% of patients who were not diagnosed with GDM (35,160
patients not diagnosed) must have missed GDM screening. We estimate this to be 1793
patients (5.1% of 35,160) out of a total population of 76,663 births, meaning approximately
2.3% of mothers missing GDM screening.
In SA, 14.2% of patients who were not diagnosed with GDM (5,746 patients not diagnosed)
must have missed GDM screening. We estimate this to be 816 patients (14.2% of 5,746) out of
a total population of 19,909 births, meaning approximately 4.1% of mothers missing GDM
screening.
NGDR registration
The distribution of OGTTs and GCTs showed peaks consistent with screening for GDM using
these tests prior to registration (Fig 4). Patterns in BGLU, including fasting glucose, and
HbA1c were less obvious (Fig 4).
In Victoria from 2012 to 2013 GDM diagnosis rates increased from 7.0% to 7.9% whilst
GDM register registration rates remained stable around 87%-88% (Table 3). In South Austra-
lia, GDM diagnosis rates rose from 7.2% to 8.2% whilst GDM register registration rates
dropped from 78% to 70% (Table 3).
Follow-up testing for risk of diabetes
OGTT testing in the recalled population (see Methods) was most pronounced between eight
and 30 weeks after registration (Fig 5). This period overlaps with the timing of NGDR
Impact of a national gestational diabetes register
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reminder mail-out. The peak OGTT activity occurred almost exactly at six weeks postnatally.
This can be seen in Fig 6 (almost all GDM screening activity is OGTT, 11% are GCT in South
Australia). The six week postnatal activity suggests most follow-up occurs independently of
mail-out (before women receive the letter) and corresponds to clinical best practice. We were
unable to attribute testing activity after this point in time to the mail-out or women being fol-
lowed up as part of usual care. We assume that if mail-out was having an impact it would
prompt women who did not attend their six week test to have a test sometime after which
would be picked up as another sharp spike in testing activity corresponding with the monthly
mail-out from the NGDR.
To further assess potential influence of mail-out, patterns of six week postpartum follow-up
testing were graphed for calendar years 2010–2013 (Fig 6). If the mail out, rather than a regular
planned appointment, was influential in obtaining appointments for postnatal review a clear
alignment of testing activity should have been evident in years 2012 and 2013 in response. This
was not seen. Negligible activity at around 52 and 104 weeks postpartum (see Fig 5) suggests
the mail-out is of little benefit for annual follow-up.
Fig 4. Pathology testing for 2012–2013 NGDR registered women in the weeks prior to GDM registration (at time
0).
https://doi.org/10.1371/journal.pone.0200832.g004
Table 3. GDM and NGDR registration rates 2012–2013.
Victoria Victoria South Australia South Australia
2012 2013 2012 2013
Total Pregnancies 76,726 76,663 20,328 19,909
Pregnancies with a GDM diagnosis on birth record 5,413 6,045 1,468 1,636
GDM diagnosis rate 7.0% 7.9% 7.2% 8.2%
Pregnancies with NGDR registration 4,701 5,262 1,147 1,146
Registration rate 88% 87% 78% 70%
https://doi.org/10.1371/journal.pone.0200832.t003
Impact of a national gestational diabetes register
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Absolute screening and recall rates cannot be determined due to incomplete pathology data
coverage. Nonetheless, based on the number of diagnostic test results we have for mothers
diagnosed with GDM in perinatal data collections (who must therefore have had at least one
test undertaken), we were able to estimate that laboratory data available to us represented 69%
and 82% of all GDM testing for Victoria and South Australia respectively. The South Australia
state-specific diabetes register (prior to July 2011) demonstrated improved patterns of screen-
ing and stable levels of recall from 2010 to 2013 (Table 2). In comparison, Victoria exhibited a
greater relative increase in both screening and recall activity over the same period (Table 2),
noting this jurisdiction started from a lower base for screening and hence had more scope for
improvement.
Conclusions
The GRHANITE privacy-preserving linkage technologies enabled us to achieve the first suc-
cessful linkage between different data sources, allowing an evaluation of the NGDR’s perfor-
mance. Across 12.2 million clinical records, GRHANITE linkage identified the 26–28 week
Fig 5. Laboratory testing in Victoria and South Australia relative to the date of GDM registration; 1 year before
registration -> 2 years after registration.
https://doi.org/10.1371/journal.pone.0200832.g005
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OGTT or GCT and six week postnatal OGTT results, but found no evidence of annual follow-
up testing, prompted by reminder letters or otherwise, as demonstrated by a lack of diabetes-
related blood testing activity at one year and beyond.
NGDR registration rates were higher in Victoria, perhaps related to a campaign to remind
diabetes educators to register women. Although there was an increase in registration rates in
2013 in Victoria, the rate of new diagnoses of GDM in the birth registries outstripped the rate
of new entries in the NGDR. With GDM diagnostic rates increasing, NGDR registrations
should be increasing also. These were demonstrated to be static or falling. This finding shows
the importance of periodically reminding diabetes educators about the register. Note that data
acquired by this method could also be used to identify providers with poor registration rates.
Our estimated rates for GDM screening at 26–28 weeks are high at 97.7% in Victoria and
96% in South Australia (2012–2013).
To the best of our knowledge, NGDR is the world’s first national GDM registry. Evaluation
of its performance is useful for others considering setting up similar systems. The sharp peak
in type 2 diabetes diagnostic testing at six weeks is evidence of systematic six week
Fig 6. Screening and recall 2010–2013, Victoria and SA.
https://doi.org/10.1371/journal.pone.0200832.g006
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appointments being made at time of birth. Reminder letters sent by the register to mothers
and family physicians for screening follow-up are forecast to arrive after this appointment
(according to NGDR timelines). There is no evidence that subsequent letters promoted further
follow-up around 12 or 24 months.
Uptake of annual follow-up screening for type 2 diabetes was unsatisfactory (Fig 5) and
lower than for other screening programs for women, such as breast screening 54% [12] Pap
smears 56% [13] or bowel screening 40% [14]. One explanation for this low uptake of testing is
that women who have had GDM do not consider themselves to be at high risk for development
of type 2 diabetes [15]. Many people do not think diabetes is a serious health problem [16]
which may be another reason for lack of annual follow-up. More concrete conditions, like can-
cer, show higher screening [17] because there is a pathology that people recognise and fear.
Diabetes is abstract, asymptomatic, insidious, and needs lifelong commitment to prevention
and management. Promoting a delayed benefit from lifestyle changes runs counter to the fac-
tors that we know to predict engagement in prevention activities.
It has been shown that if a woman has FPG <6.0 mmol/l at the time of discharge postpar-
tum, she has a low likelihood of postnatal diabetes [18,19]. Follow-up screening could be more
effectively targeted if instead of the six week OGTT, Fasting Plasma Glucose (FPG) was tested
prior to discharge from hospitals. We know from women with type 1 diabetes that the insulin
resistant effect of pregnancy declines rapidly, within minutes of the placenta being delivered. It
can be argued that if FPG was normal in the immediate postnatal period it is likely to be so, six
weeks later. It seems reasonable to do immediate postnatal fasting plasma glucose tests and
only proceed to formal OGTT if FPG>6.0 mmol/l.
We did not account for the potential impact of the new International Association of Diabe-
tes and Pregnancy (IADPSG) guidelines for diagnosing GDM as they were not introduced
until after the 2012–2013 study period reported here [20,21]. Up to one third more women are
forecast to be diagnosed with GDM than with previous criteria [19,22]. When the new criteria
were introduced, no consideration was given to long-term follow-up of those women who are
now diagnosed with GDM because of the change in criteria and who are likely to be at lower
risk of developing type 2 diabetes. A further use of our data linkage will be for a longitudinal
study with stratification of risk so that those at highest risk can be followed up more frequently
and more intensive efforts made for recall.
Limitations of the study which arise from privacy protection include an inability to manually
validate record linkage quality. Other mechanisms were employed to verify the linkage efficacy:
almost 87% of all registrations had a corresponding birth record demonstrated by the record
linkage. Erroneous linkage would show random associations between registration and birth
which was not found. There were also very clear indicators of 26–28 week antenatal and six
week postnatal GDM testing as well as close association between GDM diagnosis and subse-
quent NGDR registration (Fig 3). There is no such thing as perfect record linkage unless one-
to-one unique identifier matching is possible. In large populations small errors (sensitivity or
specificity) have a negligible impact on population trends. This study utilises population trends
and differences in percentage between sub-populations in its analysis building on the confi-
dence of the matching between registration and birth and pre and postnatal testing patterns.
Engaging women who have had GDM in follow-up programs is difficult [3,23]. Social mar-
keting may be required to change the perception of prediabetes as a significant predictor of
diabetes. Convenience, systems of care, and recall systems have been cited as important deter-
minants of effective annual screening [24] and their provision in Family Practice does seem to
improve women’s participation [4].
Routine booking of a six week postnatal appointment at the time of baby birth contrinuted
to 43.0–58.4% of mothers obtaining type 2 diabetes follow-up testing at six weeks (Table 2).
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The register which sends out an information pack on first registration after the 28wk OGTT
may act as a reminder to attend this pre-booked appointment with an increase in testing in
Victoria of up-to 8.9% following the advent of the register (49.5% before, 58.4% 2012 –Table 2)
(no change in South Australia where they had a register previously). From six weeks after the
birth onwards there was no evidence of periodic register mail-outs having any effect whatso-
ever on encouraging mothers to seek further annual type 2 diabetes follow-up testing.
One use for the NGDR could be to populate Family Practice-based registers of women who
have had GDM. Patients are more likely to act when the message comes from their family phy-
sician. Early evidence from Primary Care research suggests that managing recall and testing of
women who have had GDM at the local level is likely to be more effective than letters coming to
these women from a national source [4].
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